Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event.

Yeh IT, Martin MA, Robetorye RS, Bolla AR, McCaskill C, Shah RK, Gorre ME, Mohammed MS, Gunn SR.

Mod Pathol. 2009 Sep;22(9):1169-75. doi: 10.1038/modpathol.2009.78. Epub 2009 May 15.

2.

Molecular classification of melanomas and nevi using gene expression microarray signatures and formalin-fixed and paraffin-embedded tissue.

Koh SS, Opel ML, Wei JP, Yau K, Shah R, Gorre ME, Whitman E, Shitabata PK, Tao Y, Cochran AJ, Abrishami P, Binder SW.

Mod Pathol. 2009 Apr;22(4):538-46. doi: 10.1038/modpathol.2009.8. Epub 2009 Mar 6.

3.

Atypical 11q deletions identified by array CGH may be missed by FISH panels for prognostic markers in chronic lymphocytic leukemia.

Gunn SR, Hibbard MK, Ismail SH, Lowery-Nordberg M, Mellink CH, Bahler DW, Abruzzo LV, Enriquez EL, Gorre ME, Mohammed MS, Robetorye RS.

Leukemia. 2009 May;23(5):1011-7. doi: 10.1038/leu.2008.393. Epub 2009 Jan 22. No abstract available.

PMID:
19158838
4.

Array CGH analysis of chronic lymphocytic leukemia reveals frequent cryptic monoallelic and biallelic deletions of chromosome 22q11 that include the PRAME gene.

Gunn SR, Bolla AR, Barron LL, Gorre ME, Mohammed MS, Bahler DW, Mellink CH, van Oers MH, Keating MJ, Ferrajoli A, Coombes KR, Abruzzo LV, Robetorye RS.

Leuk Res. 2009 Sep;33(9):1276-81. doi: 10.1016/j.leukres.2008.10.010. Epub 2008 Nov 21.

PMID:
19027161
5.

Whole-genome scanning by array comparative genomic hybridization as a clinical tool for risk assessment in chronic lymphocytic leukemia.

Gunn SR, Mohammed MS, Gorre ME, Cotter PD, Kim J, Bahler DW, Preobrazhensky SN, Higgins RA, Bolla AR, Ismail SH, de Jong D, Eldering E, van Oers MH, Mellink CH, Keating MJ, Schlette EJ, Abruzzo LV, Robetorye RS.

J Mol Diagn. 2008 Sep;10(5):442-51. doi: 10.2353/jmoldx.2008.080033. Epub 2008 Aug 7.

6.

Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants.

Skaggs BJ, Gorre ME, Ryvkin A, Burgess MR, Xie Y, Han Y, Komisopoulou E, Brown LM, Loo JA, Landaw EM, Sawyers CL, Graeber TG.

Proc Natl Acad Sci U S A. 2006 Dec 19;103(51):19466-71. Epub 2006 Dec 12.

7.
9.
10.

Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop.

Roumiantsev S, Shah NP, Gorre ME, Nicoll J, Brasher BB, Sawyers CL, Van Etten RA.

Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10700-5. Epub 2002 Jul 29.

11.

Molecular mechanisms of resistance to STI571 in chronic myeloid leukemia.

Gorre ME, Sawyers CL.

Curr Opin Hematol. 2002 Jul;9(4):303-7. Review.

PMID:
12042704
12.

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification.

Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL.

Science. 2001 Aug 3;293(5531):876-80. Epub 2001 Jun 21.

13.

Distinct categories of immunologic changes in frail elderly.

Fahey JL, Schnelle JF, Boscardin J, Thomas JK, Gorre ME, Aziz N, Sadeghi H, Nishanian P.

Mech Ageing Dev. 2000 May 18;115(1-2):1-20.

PMID:
10854626

Supplemental Content

Loading ...
Support Center